. home.aspx



Biosimilars in the Pipeline

January 02, 2020 / Managed Healthcare Executive

“Biologics are innovative treatment options for patients affected by debilitating and life-threatening diseases; however, they are often associated with high costs and limited patient access. Fortunately, more affordable options for many patients who rely on biologic treatments are beginning to enter the market: biosimilars,” reads an excerpt from, Why Biosimilars Are Important for Patients, published in February 2018 by the Biosimilars Council, a division of the Association for Accessible Medicines. “The launch of new biosimilars over the next decade could save consumers as much as $250 billion and boost access to biologic treatments for an additional 1.2 million patients by 2025,” according to the article.